Filter news by category :
01 Mar 2023 | [Ga-68]EMP-100, Collaborations
A case of a 56-year-old female former smoker with stage IV EGFR mutation-positive NSCLC (lymphogenic, pulmonary, hepatic, and cerebral metastases is presented. Stage: cT3, cN3, cM1b) and concomitant MET exon 14 skipping mutation. After multiple pretreatments including radiochemotherapy and...
11 Apr 2022 | Collaborations, EMI-137
Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal metastases (NM) and to identify...
06 Dec 2021 | [Ga-68]EMP-100, Collaborations
This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in metastases and primary RCC. Conclusion: Visualization of c-MET expression with 68Ga-EMP-100 PET imaging...
21 May 2021 | Collaborations, EMI-137
This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient using multicolor fluorescence...
21 Mar 2018 | Collaborations
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s second biggest cancer killer....
02 Jun 2017 | Collaborations
Edinburgh Molecular Imaging is proud to support the University of Edinburgh team.The researchers aim to create new chemicals – known as tracers – to illuminate these unstable plaques in patients. The tracers – which contain small amounts of radioactivity – are injected into the bloodstream and...
19 Sep 2016 | Collaborations, Press Releases
Edinburgh Molecular Imaging is part of an EPSRC funded consortium, led by Dr Jon Shephard of Heriot-Watt University in collaboration with Professor David Jayne from the University of Leeds to develop a revolutionary new bowel cancer surgery tool that will enable surgeons to carry out operations...
07 Apr 2016 | Collaborations, Press Releases
Edinburgh and Paris, April 6th, 2016 – Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea's...
09 Mar 2016 | Collaborations, EMI-137
Edinburgh Molecular imaging Ltd (EM Imaging) announced today that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase the development and adoption of...